DiaMedica Therapeutics Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
DiaMedica Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
  • DiaMedica Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$6.88M, a 33.5% decline year-over-year.
  • DiaMedica Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$24.1M, a 24.3% decline year-over-year.
  • DiaMedica Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$21.3M, a 51.9% decline from 2022.
  • DiaMedica Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$14M, a 2.6% decline from 2021.
  • DiaMedica Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$13.6M, a 7.46% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$24.1M -$6.88M -$1.73M -33.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$22.4M -$5.64M -$897K -18.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$21.5M -$5.74M -$220K -3.99% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$21.3M -$5.85M -$1.88M -47.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 -$19.4M -$5.16M -$2.03M -64.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$17.4M -$4.74M -$1.38M -40.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$16M -$5.52M -$1.99M -56.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$14M -$3.97M -$727K -22.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 -$13.3M -$3.13M +$288K +8.43% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$13.6M -$3.36M +$1K +0.03% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$13.6M -$3.54M +$83K +2.29% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$13.6M -$3.25M +$1.02M +23.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 -$14.7M -$3.42M -$97K -2.92% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$14.6M -$3.37M -$657K -24.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$13.9M -$3.62M -$1.22M -50.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$12.7M -$4.27M -$1.5M -54.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 -$11.2M -$3.32M -$658K -24.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$10.5M -$2.71M +$33K +1.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$10.6M -$2.4M +$1.02M +29.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$11.6M -$2.77M -$652K -30.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 -$10.9M -$2.66M -$1.17M -79% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$9.77M -$2.74M -$891K -48.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$8.88M -$3.42M -$2.12M -162% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 -$6.76M -$2.12M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-23
Q3 2018 -$1.49M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$1.85M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$1.31M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.